Bühler Klaus, Roeder Claudia, Schwarze Juan-Enrique, Lispi Monica, Allignol Arthur, Falla Edel, Lukyanov Vasily, D Hooghe Thomas, Fischer Robert
Scientific Clinical Centre for Endometriosis, University Hospitals of Saarland, Saarbrücken, Germany; Department of Gynaecology, Jena-University Hospital-Friedrich Schiller University, Jena, Germany.
Pharma Value Consulting, Oberwil, Switzerland.
Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):188-202. doi: 10.1016/j.bpobgyn.2022.02.002. Epub 2022 Feb 16.
This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based on data from a German in vitro fertilization registry (RecDate). Pregnancy and live birth rates from the RecDate real-world evidence study over three complete assisted reproductive technology (ART) cycles using the same gonadotropin drug were used as clinical inputs. Costs related to ART treatment and to drugs were obtained from public sources. Treatment with r-hFSH-alfa resulted in higher adjusted cumulative live birth rates versus hMG-HP after one (25.3% vs. 22.3%), two (30.9% vs. 27.5%), and three (31.9% vs. 28.6%) ART cycles. Costs per live birth were lower with r-hFSH-alfa versus hMG-HP after one (€17,938 vs. €20,054), two (€18,251 vs. €20,437), and three (€18,473 vs. €20,680) ART cycles. r-hFSH-alfa was found to be a cost-effective strategy compared with hMG-HP over three cycles.
这是一项基于德国体外受精登记处（RecDate）数据的回顾性真实世界证据分析，比较了重组人促卵泡激素α（r-hFSH-alfa）与高纯度尿促性素（hMG-HP）每例活产的成本。RecDate真实世界证据研究中，使用相同促性腺激素药物进行三个完整辅助生殖技术（ART）周期的妊娠率和活产率被用作临床输入数据。ART治疗和药物相关成本来自公共来源。在进行一个（25.3%对22.3%）、两个（30.9%对27.5%）和三个（31.9%对28.6%）ART周期后，与hMG-HP相比，r-hFSH-alfa导致更高的调整后累积活产率。在进行一个（17,938欧元对20,054欧元）、两个（18,251欧元对20,437欧元）和三个（18,473欧元对20,680欧元）ART周期后，r-hFSH-alfa每例活产的成本低于hMG-HP。研究发现，在三个周期内，与hMG-HP相比，r-hFSH-alfa是一种具有成本效益的策略。
